His wife, Terri DeNeui, a nurse practitioner and founder of their company Evexias Health Solutions, presented information from a survey of 508 patients treated with various peptides that said 19% reported uncomfortable side effects and less than 1% experienced an adverse event
Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, et al
The increase in risk was small approximately three to four additional cases per 10,000 patients treated with GLP-1s over 18 months, but clinicians and patients should be aware of this potential association. Researchers said while the risk is low, the rising use of GLP-1s in patients with and without Type 2 diabetes warrants special attention to medication safety
The GLP-1 class includes drugs FDA-approved for type 2 diabetes (since exenatide in 2005) and for chronic weight management (liraglutide / Saxenda in 2014)